Literature DB >> 12148889

The CD19 compartment in myeloma includes a population of clonal cells persistent after high-dose treatment.

Thomas Rasmussen1, Linda Jensen, Hans Erik Johnsen.   

Abstract

Peripheral blood-localized clonal cells in patients with multiple myeloma (MM) have been reported to be insensitive to chemotherapy and it has been suggested that these cells may include the proliferative compartment in myeloma. In this study, circulating clonal CD19+ cells levels were determined in 10 patients with MM by performing patient-specific RT-PCR on single flow-sorted CD19+ cells. A variable proportion of CD+ cells being clonal were identified (0.101-6.130%, mean 1.019%). In 10/10 MM patients clonal CD19+ cells were found after high-dose treatment and peripheral blood stem cell transplantation. In conclusion, CD19+ clonal cells include a population of cells persistent after high dose chemotherapy that may be responsible for relapse.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12148889     DOI： 10.1080/10428190290021524

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


  4 in total

Review 1.  The myeloma stem cell concept, revisited: from phenomenology to operational terms.

Authors:  Hans Erik Johnsen; Martin Bøgsted; Alexander Schmitz; Julie Støve Bødker; Tarec Christoffer El-Galaly; Preben Johansen; Peter Valent; Niklas Zojer; Els Van Valckenborgh; Karin Vanderkerken; Mark van Duin; Pieter Sonneveld; Martin Perez-Andres; Alberto Orfao; Karen Dybkær
Journal:  Haematologica       Date:  2016-11-10       Impact factor: 9.941

2.  Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma.

Authors:  Thomas Rasmussen; Jacob Haaber; Inger Marie Dahl; Lene M Knudsen; Gitte B Kerndrup; Marianne Lodahl; Hans E Johnsen; Michael Kuehl
Journal:  Haematologica       Date:  2010-05-29       Impact factor: 9.941

Review 3.  Multiple myeloma-initiating cells.

Authors:  Naoki Hosen
Journal:  Int J Hematol       Date:  2013-02-19       Impact factor: 2.490

4.  Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion.

Authors:  Hiroaki Kitamura; Yasushi Kubota; Kyosuke Yamaguchi; Kazuharu Kamachi; Atsujiro Nishioka; Masako Yokoo; Takero Shindo; Toshihiko Ando; Kensuke Kojima; Shinya Kimura
Journal:  Intern Med       Date:  2017-11-20       Impact factor: 1.271
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.